Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 1/20 | 0.66 |
| ▸ | GLUL | P15104 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | OTC | P00480 | 1/20 | 0.56 |
| ▸ | GSR | P00390 | 1/20 | 0.54 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.53 |
| ▸ | GRM8 | O00222 | 1/20 | 0.53 |
| ▸ | GRM6 | O15303 | 1/20 | 0.53 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.53 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1662220 | 1.00 | BHMT (0.66) | BHMTGLULALDH1A1TDP1OTC | |
| SCHEMBL158653 | 1.00 | BHMT (0.66) | BHMTGLULALDH1A1TDP1OTC | |
| SCHEMBL1978027 | 0.94 | BHMT (0.69) | BHMTGLULTDP1OTCGSR | |
| SCHEMBL12648651 | 0.94 | BHMT (0.69) | BHMTGLULTDP1OTCGSR | |
| SCHEMBL13997086 | 0.94 | BHMT (0.69) | BHMTGLULTDP1OTCGSR | |
| Water SCHEMBL21747431 | 0.92 | BHMT (0.67) | BHMTGLULTDP1OTCGSR | |
| Hydrochloric Acid SCHEMBL21747394 | 0.92 | BHMT (0.67) | BHMTGLULTDP1OTCGSR | |
| SCHEMBL21747440 | 0.92 | BHMT (0.67) | BHMTGLULTDP1OTCGSR | |
| SCHEMBL21747426 | 0.92 | BHMT (0.67) | BHMTGLULTDP1OTCGSR | |
| Water SCHEMBL21747391 | 0.92 | BHMT (0.67) | BHMTGLULTDP1OTCGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2443 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589097-B2 | Apilimod compositions and methods of use | OrphAl Therapeutics Inc. (US) | 2026-03-31 | — | — | US | claimed |
| EP-4623932-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | National University Corporation Chiba University (JP) | 2025-10-01 | — | — | EP | claimed |
| CN-118853834-B | Detection system and detection method for tobramycin based on CRISPR-Cas12a and hybridization chain reaction | 江苏第二师范学院 | 2025-06-24 | — | — | CN | claimed |
| WO-2025065271-A1 | METHODS AND DEVICES FOR TREATING DEPRESSION | Liangzhu Laboratory (CN) | 2025-04-03 | — | — | WO | claimed |
| WO-2025030033-A1 | APILIMOD COMPOSITIONS AND METHODS OF USE | ORPHAI THERAPEUTICS INC. (US) | 2025-02-06 | — | — | WO | claimed |
| US-12194201-B2 | Silica nanoparticle doped conductive polymer | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-01-14 | — | — | US | claimed |
| EP-4475953-A1 | NMDAR ANTAGONISTS PREVENT AGEING AND AGING-ASSOCIATED CONDITIONS AND DISEASES THROUGH INCREASING 20S PROTEASOME ACTIVITY | SAHIN, Fikret (TR) | 2024-12-18 | — | — | EP | claimed |
| CN-119095622-A | NMDAR antagonists prevent aging and aging-related conditions and diseases by increasing 20S proteasome activity | 菲克雷特·萨欣 | 2024-12-06 | — | — | CN | claimed |
| CN-118853834-A | Detection system and detection method for tobramycin based on CRISPR-Cas12a and hybridization chain reaction | 江苏第二师范学院 | 2024-10-29 | — | — | CN | claimed |
| CN-118684620-A | Betel nut alkaloid and preparation method and application thereof | 暨南大学 | 2024-09-24 | — | — | CN | claimed |
| EP-0797442-A4 | TREATMENT OF OPTIC NEURITIS | MASSACHUSETTS EYE & EAR INFIRM (US) | 1998-04-15 | — | — | EP | claimed |
| EP-0797442-A1 | TREATMENT OF OPTIC NEURITIS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 1997-10-01 | — | — | EP | claimed |
| EP-0778023-A1 | Neuroprotective agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-06-11 | — | — | EP | claimed |
| WO-1996000073-A1 | TREATMENT OF OPTIC NEURITIS | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 1996-01-04 | — | — | WO | claimed |
| EP-0557290-A1 | TREATMENT OF AIDS DEMENTIA, MYELOPATHY, PERIPHERAL NEUROPATHY, AND VISION LOSS | The Children's Medical Center Corporation (US) | 1993-09-01 | — | — | EP | claimed |
| EP-0557290-A4 | TREATMENT OF AIDS DEMENTIA, MYELOPATHY, PERIPHERAL NEUROPATHY, AND VISION LOSS. | CHILDRENS MEDICAL CENTER (US) | 1993-07-14 | — | — | EP | claimed |
| WO-1992003137-A1 | TREATMENT OF AIDS DEMENTIA, MYELOPATHY, PERIPHERAL NEUROPATHY, AND VISION LOSS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1992-03-05 | — | — | WO | claimed |
| EP-0432994-A2 | Excitatory amino acid antagonists as anti-emetic drugs | Olney, John William (US) | 1991-06-19 | — | — | EP | claimed |
| US-4994446-A | Drug system | RAMOT - UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) | 1991-02-19 | — | — | US | claimed |
| WO-1988007851-A1 | LIPOSOME ENTRAPPED N-METHYL-D-ASPARTATE RECEPTOR BLOCKERS | INNOVATIVE THERAPEUTICS CORPORATION (US) | 1988-10-20 | — | — | WO | claimed |